Inhaled ß2 agonist drugs used to treat asthma do not exert ergogenic effects and should be taken off the World Anti-Doping Agency (WADA) banned list. That’s the key message of a new German study set up to review the literature on the effects of these drugs in non-asthmatic competitive athletes and to assess their performance-enhancing effects.